Comparing the Relationship of Taxol-Based Chemotherapy Response with P-glycoprotein and Lung Resistance-Related Protein Expression in Non-Small Cell Lung Cancer

Lung

Volumn 181, Issue 5, 2003, Pages 267-273

  Chiou, J F ^a   Liang, J A ^b   Hsu, W H ^b   Wang, J J ^c   Ho, S T ^d   Kao, A ^b  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Lung resistance protein expression; Non small cell lung cancer; P glycoprotein; Taxol

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; PACLITAXEL DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG RESPONSE; EVALUATION; FEMALE; GRANULOCYTOPENIA; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG NON SMALL CELL CANCER; MALE; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIODIAGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; PROGNOSIS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0142156106     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-003-1029-7     Document Type: Article

References (21)

1. Paul DM, Johnson DH (1995) Chemotherapy for non-small cell lung cancer. In: Johnson BE, Johnson DH (eds): Lung cancer. Wiley-Liss, New York, pp 247-261
2. Smit EF, Postmus PE (1995) Chemotherapy of non-small cell lung cancer. In: Carney DN (ed): Lung cancer. The Bath Press, London, UK, pp 156-172
3. Goldstein LJ (1996) MDR1 gene expression in solid tumours. Eur J Cancer 32:1039-1050
4. Scheper RJ, Broxterman HJ, Scheffer GL, et al (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1457-1459
5. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65:230-237
6. Kao CH, Hsieh JF, Tsai SC, Ho YJ, ChangLai SP, Lee JK (2001) Paclitaxel-based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging. J Nucl Med 42:17-20
7. Kao CH, Hsieh JH, Tsai SC, Ho YJ, Lee JK (2000) Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography. Clin Cancer Res 6:820-824
8. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH (2002) Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Lung 179:197-207
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
10. Dingemans AMC, van Ark-Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, Giaccone G (1996) Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 7:625-630
11. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA (1995) Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 12:S163-S172
12. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science 258:1650-1654
13. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113
14. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP (1993) Taxol: mechanism of action and resistance. J Natl Cancer Inst Monogr 15:55-61
15. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zeheb R (1986) Taxol mechanisms of action and resistance. Ann NY Acad Sci 466:733-744
16. van-Ark-Otte J, Samelis G, Rubio G, Lopez-Saez JB, Pinedo HM, Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5:249-255
17. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 6:578-582
18. Cheng SH, Lam W, Lee ASK, Fung KP, Wu RS, Fong WF (2000) Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 164:134-142
19. Akiyama S, Chen ZS, Kitazono M, Sumizawa T, Furukawa T, Aikou T (1999) Mechanisms for resistance to anticancer agents and the reversal of the resistance. Hum Cell 12:95-102
20. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S (1999) Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647-1653
21. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM (2001) Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99:179-186